Regulatory Efficiency & Modernization
Canada’s pharmaceutical supply chain is highly regulated to ensure patient safety, but many regulatory frameworks have not evolved alongside modern distribution practices. As a result, distributors and supply chain partners face a growing burden of outdated, duplicative, or misaligned requirements that add cost, reduce efficiency, and, in some cases, undermine the outcomes they are intended to protect.
Modernizing Regulation to Support a Resilient Supply Chain
From paper-based processes to unclear guidance and disproportionate compliance obligations, regulatory friction limits innovation, constrains capacity, and diverts resources away from core supply chain functions. In an increasingly complex and globalized environment, regulatory policy must enable, not hinder, safe, efficient access to medicines.
At Vital, we advocate for targeted, risk-based regulatory modernization that strengthens system performance while maintaining Canada’s high standards for safety and quality.
Key Areas for Action
These regulatory issues, listed below, highlight clear opportunities to modernize the pharmaceutical supply chain, improving efficiency, consistency, and resilience while maintaining the highest standards of patient safety.
Advancing E-Labelling Adoption
Canada’s continued reliance on paper-based product information is increasingly misaligned with a digital, automated supply chain. Paper inserts are often removed or lost during distribution, require manual handling by distributors and pharmacies, and contribute to inefficiencies, compliance risks, and environmental waste.
Transitioning to e-labelling would:
- Provide real-time access to up-to-date product information
- Improve accessibility through multilingual and digital formats
- Enable greater automation and efficiency across the supply chain
While Health Canada has taken initial steps, such as introducing a Risk Assessment Tool, broader adoption and clear, consistent guidance are needed to fully realize system wide benefits.
Temperature Control Requirements (GUI-0069)
Temperature compliance is essential to maintaining drug safety, but current requirements create significant operational challenges.
Key issues include:
- Ambiguity in guidance, particularly regarding responsibility for providing stability data following temperature excursions
- Inconsistent interpretation and enforcement, leading to variability in audits
- Misalignment across jurisdictions
These challenges can result in unnecessary product destruction, increased costs and delays, and added strain on supply chain operations. A more harmonized, risk-based framework would protect product integrity while reducing waste, improving efficiency, and ensuring consistent application across Canada.
Precursor Regulations for Low-Risk Products
- Proposed changes to precursor control regulations risk introducing disproportionate compliance burdens without clear public health benefits.
- Pharmaceutical distributors already operate within a closed, highly regulated system, supplying licensed and controlled endpoints such as pharmacies. Expanding requirement, such as mandatory suspicious transaction reporting, enhanced background checks, and stricter controls on low-risk combination products could significantly increase administrative complexity and costs.
- These measures may also have unintended consequences, including reduced access to common over-the-counter medications and increased pressure on healthcare systems as patients seek alternatives.
- A more targeted, risk-based approach is needed, one that focuses oversight where risks are highest while preserving access and efficiency within the regulated supply chain.
Advancing E-Labelling Adoption
Canada’s continued reliance on paper-based product information is increasingly misaligned with a digital, automated supply chain. Paper inserts are often removed or lost during distribution, require manual handling by distributors and pharmacies, and contribute to inefficiencies, compliance risks, and environmental waste.
Transitioning to e-labelling would:
- Provide real-time access to up-to-date product information
- Improve accessibility through multilingual and digital formats
- Enable greater automation and efficiency across the supply chain
While Health Canada has taken initial steps, such as introducing a Risk Assessment Tool, broader adoption and clear, consistent guidance are needed to fully realize system wide benefits.
Temperature Control Requirements (GUI-0069)
Temperature compliance is essential to maintaining drug safety, but current requirements create significant operational challenges.
Key issues include:
- Ambiguity in guidance, particularly regarding responsibility for providing stability data following temperature excursions
- Inconsistent interpretation and enforcement, leading to variability in audits
- Misalignment across jurisdictions
These challenges can result in unnecessary product destruction, increased costs and delays, and added strain on supply chain operations. A more harmonized, risk-based framework would protect product integrity while reducing waste, improving efficiency, and ensuring consistent application across Canada.
Precursor Regulations for Low-Risk Products
- Proposed changes to precursor control regulations risk introducing disproportionate compliance burdens without clear public health benefits.
- Pharmaceutical distributors already operate within a closed, highly regulated system, supplying licensed and controlled endpoints such as pharmacies. Expanding requirement, such as mandatory suspicious transaction reporting, enhanced background checks, and stricter controls on low-risk combination products could significantly increase administrative complexity and costs.
- These measures may also have unintended consequences, including reduced access to common over-the-counter medications and increased pressure on healthcare systems as patients seek alternatives.
- A more targeted, risk-based approach is needed, one that focuses oversight where risks are highest while preserving access and efficiency within the regulated supply chain.
Vital’s Perspective
At Vital, we believe effective regulation is essential, but it must be modern, clear, and proportionate.
We support:
- Risk-based regulatory frameworks that align with real-world supply chain practices
- Greater harmonization across jurisdictions to reduce duplication and inconsistency
- Clear, actionable guidance that supports compliance without unnecessary burden
- Policies that enable innovation, digital transformation, and operational efficiency
Modernizing regulatory policy is not about reducing oversight—it is about improving outcomes for patients, providers, and the system as a whole.
Looking Ahead
As Canada’s pharmaceutical supply chain continues to evolve, regulatory frameworks must keep pace with advances in technology and distribution models, increasing global integration and the need for greater resilience and flexibility.
By reducing unnecessary red tape and focusing on smart, evidence-based regulation, Canada can strengthen its supply chain while maintaining the highest standards of safety and quality.
Vital will continue to advocate for regulatory approaches that support access, efficiency, and long-term system sustainability.
